May 07, 2019
Roche's takes a step- forward to treat Huntington's disease A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an antisense oligonucleotide is able to successfully lower down the production of a toxic protein that results in dysf...
Read More...
Mar 08, 2018
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyre...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper